Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xi'An Haorui Gene Technologies Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, TSUI, YUNG-SHENG M, who is the busiest examiner with 1 pending office action. This means the company's current patent prosecution is entirely dependent on the review of a single examiner within the patent office. For the practitioner, this suggests that the prosecution strategy should be highly tailored to the specific preferences and history of this one examiner.
The prosecution is limited to 1 distinct art unit. This reflects a highly focused patenting effort where the company's current interaction with the patent office is limited to a single examiner and a single technical group. This lack of distribution across different art units or examiners suggests a highly specialized invention that falls squarely within a single regulatory niche, requiring a focused and consistent legal approach during prosecution. Success in this matter will depend on a deep understanding of the assigned examiner's past rulings and technical standards within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TSUI, YUNG-SHENG M | 1 | 66.5% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701537 | HLA GENE AMPLIFICATION PRIMER, KIT, SEQUENCING LIBRARY CONSTRUCTION METHOD, AND SEQUENCING METHOD | TSUI, YUNG-SHENG M | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701537 | HLA GENE AMPLIFICATION PRIMER, KIT, SEQUENCING LIBRARY CONSTRUCTION METHOD, AND SEQUENCING METHOD | TSUI, YUNG-SHENG M | 1684 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXi'An Haorui Gene Technologies Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yung-Sheng M Tsui has the most, with 1 of Xi'An Haorui Gene Technologies Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
